Chemical formula: C₃₈H₅₂N₆O₇ Molecular mass: 704.856 g/mol PubChem compound: 148192
Atazanavir is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J05AE08 | Atazanavir | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| REYATAZ Hard capsules | European Medicines Agency (EU) | MPI, EU: SmPC |
Atazanavir is an active ingredient of these brands:
Brazil (BR)
Canada (CA)
Croatia (HR)
Cyprus (CY)
Finland (FI)
Hong Kong (HK)
Italy (IT)
Japan (JP)
Netherlands (NL)
New Zealand (NZ)
Singapore (SG)
South Africa (ZA)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
